Shimadzu and Phenomenome Discoveries Announce Exclusive Collaboration
News Jul 02, 2007
Shimadzu Corporation and Phenomenome Discoveries Inc (PDI) have agreed to integrate high mass accuracy mass spectrometry data generated on Shimadzu Corporation's LCMS-IT-TOF systems with the Phenomenome Profiler™ informatics platform.
This announcement further combines the Shimadzu Corporation's mass spectrometry product line with PDI's software tools to visualize and interpret data for biomarker discovery and global profiling studies including comparative proteomic studies.
Kozo Shimazu, Corporate Officer, Deputy General manager For Mass Spectrometry, at Shimadzu Corporation, stated, “Our collaboration with PDI has been enhanced to take into account the growing need of researchers working in biomarker discovery and comparative proteomics studies to use high mass accuracy MSn data.”
Mr. Shimazu added, “We believe that this collaboration further strengthens the relationship between Shimadzu Corporation and PDI and helps deliver a unique and integrated solution to help find components of biologically significance.”
John Hyshka, COO of Phenomenome Discoveries, said “Our agreement with Shimadzu Corporation allows investigators working in global profiling to find and identify key markers for disease using innovative mass spectrometry technology. This agreement reflects our growing commitment to develop new tools for advancing research into working with large data sets to identify key markers for disease.”
Comet "Chury's" Late BirthNews
Comets which consist of two parts, like Chury, can form after a catastrophic collision of larger bodies. Such collisions may have taken place in a later phase of our solar system, which suggests that Chury can be much younger than previously assumed. This is shown through computer simulations.READ MORE
Nanotechnology Detects Molecular Biomarker for OsteoarthritisNews
For the first time, scientists have been able to measure a specific molecule indicative of osteoarthritis and a number of other inflammatory diseases using a newly developed technology. This preclinical study used a solid-state nanopore sensor as a tool for the analysis of hyaluronic acid.READ MORE